![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, August 19, 2013 6:14:29 AM
Uploaded on Mar 9, 2008
Nanosciences and nanotechnologies represent a formidable challenge for the research community and industry. World-class infrastructure, new fundamental knowledge, novel equipment for characterisation and manufacturing, multi-disciplinary education and training for innovative and creative engineering, and a responsible attitude to societal demands are required.
This short documentary film gives a glimpse of some of the many activities that are being carried out in Europe in these fast-growing fields of research and technological development.
Nanoviricides, Inc. -- FluCide and DengueCide -- human trials 2014
per BigKahuna....
-New site construction is ahead of schedule and should finish at the least on time. (This meeting was early Monday before this info was confirmed by NNVCbob onsite observations http://investorshub.advfn.com/boards/read_msg.aspx?message_id=90997704).
-Wants to move Dengue and flu simultaneously and has the money to do it.
-Because Dengue can't be tested through a challenge protocol with patients inoculated with the virus (made sick with Dengue then treated), it may be approved with only small phase 1/2a under orphan drug/breakthrough.
-In the coming months he will be reporting progress for EKC, HSV, HIV studies and general nanoviricide tweaking.
-IMO, the biggest thing, Anil was able to develop the MERS solution in less than a week. Less than a week for the type that will be tested in EU is pretty amazing and beats the 3 weeks of the rapid in field technology they previously talked about.
-Looking for an Aspire type deal for future money needs.
-Now looking to go it alone by a strategy of contract manufacturing and alternative avenues of distribution. At this point, he sees no reason to hand over a nanoviricide license after Anil and crew have done all the work, and that license in return for the smallest percentage. (I think this could change with the right deal, a partnership with 50/50 split and the partner picks up the remaining costs plus pays huge benchmarks. Those deals are out there.)
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM